COVID-19 Is Prompting Innovation In Research Trials

As scientists race to develop a vaccine and cure for the coronavirus that causes COVID-19, a remarkable collaboration has emerged among pharmaceutical and bioscience firms that in other times compete fiercely with each other.

Promoted by the Bill and Melinda Gates Foundation weeks before the virus was declared a pandemic, the initial 15 companies — Novartis, Bristol-Myers Squibb, Eli Lilly and Gilead among them — began sharing proprietary information about compounds that showed some promise. Now calling itself COVID R&D, the group has added additional members and prompted other bioscience and research groups into similar collaborative arrangements.

The Wall Street Journal detailed the story (subscription required) of the cooperation among pharmaceutical competitors in a commentary by Safi Bahcall.

It isn’t the first time pharmaceutical firms have come together, but the speed with which the collaboration developed, as well as the financial investment and the potential revenue sacrifice of marketing a successful vaccine or cure is what makes the arrangement so unusual.

It is, however, just one of the ways the pandemic is changing the industry.

In an article on the Association of Clinical Research Professionals’ blog, Noelle Gaskill, senior vice president in research operations at SignalPath, points to the speed at which COVID-19 related clinical trials were opened. The article says “she believes industry has an opportunity to make lasting changes inspired by seeing what worked so well to launch COVID-19 trials under pressure-filled conditions.”

“The COVID-19 pandemic has demonstrated the clinical trial industry can move quickly when so inspired, Gaskill notes. ‘Now it’s time to use those lessons we learned’ to speed trial start-up in the future.”

Her comments echoed what speakers at a session of the association’s Virtual 2020 conference said. “It’s ironic, but this negative disruption is propelling vision and innovation,” said Leanne Madre, director of strategy with the Clinical Trials Transformation Initiative.

While it’s far too soon to predict what lasting changes will be made, Karen Lindsley, with the Georgia Clinical and Translational Science Alliance, told attendees the future of clinical trials will be different. The clinical trials of last year are not the clinical trials of next year.”

Photo by Mat Napo on Unsplash

Marketing Strategies: 2024 Trends and Strategies for Success
General Interest

Marketing Strategies: 2024 Trends and Strategies for Success

The Essence of Marketing Strategy: Driving Business Success (Part II)
General Interest

The Essence of Marketing Strategy: Driving Business Success (Part II)

The Essence of Marketing Strategy: Driving Business Success
General Interest

The Essence of Marketing Strategy: Driving Business Success

Mastering Task Prioritization for Stress Reduction
General Interest

Mastering Task Prioritization for Stress Reduction

Crafting the Future: Delving into AI as a College Major
General Interest Information Technology

Crafting the Future: Delving into AI as a College Major

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team
General Interest Pharma

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights
General Interest

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

#WeAreGreenKey: Spotlight on Kyle Gierke
General Interest Healthcare

#WeAreGreenKey: Spotlight on Kyle Gierke

Essential Strategies for 2024: Remote Training
General Interest

Essential Strategies for 2024: Remote Training

Steps to Nurture a Multigenerational Workforce
General Interest

Steps to Nurture a Multigenerational Workforce

Tips to Cultivate a Compelling Employer Brand
General Interest

Tips to Cultivate a Compelling Employer Brand

Green Key Names 3 New Partners in 2024
General Interest

Green Key Names 3 New Partners in 2024

#WeAreGreenKey: Spotlight on Samantha Desena 
Accounting + Finance General Interest

#WeAreGreenKey: Spotlight on Samantha Desena 

Why Companies are Already Recruiting Interns for 2025
General Interest

Why Companies are Already Recruiting Interns for 2025

Todd Gabianelli Selected as an Old Master at Purdue University 
Pharma

Todd Gabianelli Selected as an Old Master at Purdue University 

Navigating the Surge of Respiratory Illnesses Across the U.S.
General Interest

Navigating the Surge of Respiratory Illnesses Across the U.S.

Gen Z: Catalysts for Workplace Evolution in 2024
General Interest

Gen Z: Catalysts for Workplace Evolution in 2024

The Office Real Estate Dilemma
General Interest

The Office Real Estate Dilemma

#WeAreGreenKey: Spotlight on Rich Egloff
Architecture + Engineering Leadership + Management

#WeAreGreenKey: Spotlight on Rich Egloff

From the Big Quit to the Big Stay
General Interest

From the Big Quit to the Big Stay

Latest Blog Posts
View All Posts
Marketing Strategies: 2024 Trends and Strategies for Success

Marketing Strategies: 2024 Trends and Strategies for Success

In our last two articles, we delved into marketing strategies, uncovering what they are, the multiple types, how they work,...
Read More
The Essence of Marketing Strategy: Driving Business Success (Part II)

The Essence of Marketing Strategy: Driving Business Success (Part II)

With a grasp of the fundamental concept of Marketing Strategy, let’s explore its advantages in more detail and uncover the...
Read More
The Essence of Marketing Strategy: Driving Business Success

The Essence of Marketing Strategy: Driving Business Success

In the intricate world of business, a marketing strategy serves as the cornerstone upon which companies build their path to...
Read More